<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01441947</url>
  </required_header>
  <id_info>
    <org_study_id>11-208</org_study_id>
    <nct_id>NCT01441947</nct_id>
  </id_info>
  <brief_title>Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer</brief_title>
  <official_title>A Phase II Trial of Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer With Involvement of Bone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Exelixis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study drug cabozantinib works by inhibiting several different proteins which are believed&#xD;
      to be involved in breast cancer tumor growth, its ability to spread, and its ability to form&#xD;
      new blood vessels. This drug has been used in other research studies and information from&#xD;
      those other research studies suggests that this drug may help to prevent cancer growth.&#xD;
&#xD;
      The single agent portion of this study is now closed to accrual. This research study is now&#xD;
      examining the efficacy of cabozantinib in combination with fulvestrant for treatment of&#xD;
      hormone-receptor-positive breast cancer that has spread to bone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cabozantinib will be taken orally once a day in cycles of 28 days (4 weeks). Fulvestrant will&#xD;
      be given intramuscularly on days 1 and 15 of cycle 1 and on day 1 of all subsequent cycles.&#xD;
&#xD;
      On Day 1 of each cycle subjects will have the following tests and procedures:&#xD;
&#xD;
        -  Performance status&#xD;
&#xD;
        -  Physical exam&#xD;
&#xD;
        -  Vital signs&#xD;
&#xD;
        -  Routine blood samples&#xD;
&#xD;
        -  Blood and urine samples to look at bone markers (Cycle 1 through 6 only)&#xD;
&#xD;
      Subjects will also have the following additional tests and procedures:&#xD;
&#xD;
        -  Tumor assessment by Computed Tomography (CT) scan and bone scan at Cycle 3, then every&#xD;
           12 weeks&#xD;
&#xD;
        -  Blood or urine pregnancy test (if applicable) on Day 1 of Cycles 1, 2, 4, then every 12&#xD;
           weeks&#xD;
&#xD;
        -  Urine sample and blood test for thyroid function (Cycle 1, 3, 5, then every 6 weeks)&#xD;
&#xD;
        -  Blood test for breast cancer tumor marker (Cycle 1 and 4, then every 6 weeks)&#xD;
&#xD;
        -  Pain questionnaire and painkiller medication diary at 7-day intervals during Week 3,&#xD;
           Week 6, and every 6 weeks thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Scan Response Rate</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the bone scan response rate in patients with hormone-receptor-positive breast cancer with bone metastases receiving cabozantinib. Bone scan response rate will be defined as the percentage of patients experiencing a complete resolution or significant improvement in the bone scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate overall response rate (ORR) (defined as the percentage of patients experiencing a complete response or partial response)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate Progression Free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on bone and tumor markers</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the effects of cabozantinib on biochemical markers of bone turnover and tumor markers</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cabozantinib plus fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy with cabozantinib 60 mg daily plus fulvestrant 500 mg monthly Intramuscularly (IM)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <description>Part of combination arm</description>
    <arm_group_label>Cabozantinib plus fulvestrant</arm_group_label>
    <other_name>XL184</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>part of combination arm</description>
    <arm_group_label>Cabozantinib plus fulvestrant</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clear evidence of metastases to bone on isotope bone scan&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic Estrogen-receptor-positive (ER+)&#xD;
             and/or Progesterone-receptor-positive (PR+) and Human Epidermal Growth Factor Receptor&#xD;
             (HER) 2 negative breast cancer&#xD;
&#xD;
          -  Received at least one prior line of hormonal or chemo-therapy for metastatic disease&#xD;
&#xD;
          -  must be post menopausal&#xD;
&#xD;
          -  Recovered from toxicities related to prior treatment, except alopecia, lymphopenia, or&#xD;
             other non-clinically significant Adverse Events (AEs)&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Adequate organ and marrow function&#xD;
&#xD;
          -  Sexually active fertile subjects and their partners must agree to use medically&#xD;
             accepted methods of contraception&#xD;
&#xD;
          -  Able to lie flat for up to 45 minutes for imaging studies&#xD;
&#xD;
          -  Able to swallow capsules or tablets&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Has experienced clinically-significant hematemesis or hemoptysis of &gt; 0.5 teaspoons of&#xD;
             red blood, or other signs indicative of pulmonary hemorrhage within 3 months before&#xD;
             the first dose of study treatment&#xD;
&#xD;
          -  Untreated, symptomatic or uncontrolled brain metastasis requiring current treatment&#xD;
             including steroids and anti-convulsants&#xD;
&#xD;
          -  more than 1 prior line of chemotherapy for treatment of metastatic breast cancer&#xD;
&#xD;
          -  prior treatment with fulvestrant&#xD;
&#xD;
          -  Requires concomitant treatment, in therapeutic doses, with anticoagulants such as&#xD;
             warfarin or coumadin-related agents, thrombin or Factor Xa inhibitors, and&#xD;
             antiplatelet agents (eg, clopidogrel)&#xD;
&#xD;
          -  Uncontrolled or significant intercurrent illness&#xD;
&#xD;
          -  Gastrointestinal disorders, particularly those associated with a high risk of&#xD;
             perforation or fistula formation&#xD;
&#xD;
          -  Active infection requiring systemic treatment&#xD;
&#xD;
          -  Serious non-healing wound/ulcer/bone fracture&#xD;
&#xD;
          -  History of organ transplant&#xD;
&#xD;
          -  Concurrent uncompensated hypothyroidism or thyroid dysfunction&#xD;
&#xD;
          -  Previously-identified allergy or hypersensitivity to components of the study treatment&#xD;
             formulation&#xD;
&#xD;
          -  Diagnosis of another malignancy, requiring systemic treatment, within the last 2&#xD;
             years, unless non-melanoma skin cancer, in-situ carcinoma of the cervix, or&#xD;
             superficial bladder cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven J Isakoff, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 22, 2011</study_first_submitted>
  <study_first_submitted_qc>September 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2011</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Steven J Isakoff, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator, Attending Physician in Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>ER+</keyword>
  <keyword>PR+</keyword>
  <keyword>Human Epidermal Growth Factor Receptor (HER) 2 negative</keyword>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

